Halberd Corporation (OTCMKTS:HALB) has gained momentum after announcing a provisional patent application filing with the USPTO. The patent cover extracorporeal removal of cytokines, antigens, and proteins related to obesity from a patient’s blood.
On Monday, HALB stock gained 0.40% at $0.0258 with more than 1.33 million shares, compared to its average volume of 8.75 million shares. The stock has moved within a range of $0.0257 – 0.0300 after opening the trade at $0.0300.
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
The removal of the obesity0assocated target elements can eliminate or minimize the negative personal health issues that result due to obesity. In addition, the company’s scientists discovered that the presence of some inflammatory cytokines related to Alzheimer’s disease and PTSD in blood had a connection to the propensity for obesity. Most importantly, the company’s work in removing inflammatory cytokines, antigens, and excitatory neurotransmitters from Cerebral Spinal Fluid for PTSD treatment and from blood and CFS for AD treatment offered the foundation for the benefits relative to obesity treatment.
CEO William Hartman said that it is expected that the treatment processes will be simple, just like donating blood, and will be safe. He noted that a patient would have a needle to the vein in clinical settings, and blood will flow through the treatment devices to cleanse it. Therefore in the coming days, HALB is worth watching.